Compare AUGO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUGO | CELC |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | 1462 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.0B |
| IPO Year | N/A | 2017 |
| Metric | AUGO | CELC |
|---|---|---|
| Price | $60.30 | $88.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $67.60 | ★ $112.56 |
| AVG Volume (30 Days) | 700.8K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.05 | N/A |
| Revenue Next Year | $17.09 | $720.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.55 | $11.54 |
| 52 Week High | $110.32 | $151.02 |
| Indicator | AUGO | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 31.63 |
| Support Level | $59.30 | $83.77 |
| Resistance Level | $77.01 | $117.61 |
| Average True Range (ATR) | 4.07 | 7.68 |
| MACD | -0.96 | -3.25 |
| Stochastic Oscillator | 29.98 | 9.24 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.